By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Relypsa, Inc. 

5301 Patrick Henry Drive

Santa Clara  California  95054  U.S.A.
Phone: 408-200-9500 Fax: n/a


SEARCH JOBS



Segment
Start Up





Company News
Relypsa (RLYP) Presents Veltassa Phase IV Data Showing Consistent Efficacy And Safety Whether Taken With Or Without Food In Patients With Hyperkalemia 4/20/2017 10:43:39 AM
A Revealing Conversation With Booming Bay Area Biotech Relypsa (RLYP)’s President Scott Garland 4/20/2017 6:05:27 AM
Relypsa (RLYP) Release: FDA Approves Supplemental New Drug Application For Veltassa Removing Boxed Warning Regarding Drug-Drug Interactions 11/28/2016 7:32:51 AM
Relypsa (RLYP) Announces Data On The Treatment And Impact Of Hyperkalemia To Be Presented At ASN Kidney Week 2016 11/4/2016 8:51:10 AM
Investors Elated as Relypsa (RLYP)'s Phase IV Study of Veltassa Successful 8/31/2016 6:24:51 AM
Galenica (GALN.SW) to Acquire Bay Area's Relypsa (RLYP) for $1.53 Billion 7/21/2016 6:27:21 AM
Bad News for AstraZeneca PLC (AZN) is Good News for Relypsa (RLYP) 5/27/2016 6:57:14 AM
Relypsa (RLYP) Release: Data From New Analyses Of Studies With Veltassa Presented At 53rd European Renal Association Congress 5/23/2016 10:06:06 AM
Bay Area's Relypsa (RLYP) Falls on Unimpressive Veltassa Script Data 5/17/2016 6:38:54 AM
National Kidney Foundation Recognizes Relypsa (RLYP) With Inaugural Corporate Innovator Award For First Drug Approved By FDA For Hyperkalemia In 50 Years 4/26/2016 10:27:45 AM
12345678910...
//-->